Latest Breaking News On - Xport mf 034 trial - Page 1 : comparemela.com

The oral XPO1 inhibitor selinexor in combination with ruxolitinib was associated with a tolerable and manageable adverse effect profile and elicited signals of clinical efficacy in patients with JAK inhibitor–naive myelofibrosis.

United statesSrinivask tantravahiUniversity of utah huntsman cancer instituteDynamic international prognostic scoring systemUtah huntsman cancer instituteSelinexor in combination with ruxolitinibPatients with jak inhibitor naive myelofibrosisXport mf 034 trialThe university of utah huntsman cancer institute